Day One Biopharmaceuticals, Inc. (DAWN) Insider Trading Activity

NASDAQ$21.53
Market Cap
$2.22B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
Rank in Industry

DAWN Insider Trading Activity

DAWN Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$
Sells
$

Related Transactions

About Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Insider Activity of Day One Biopharmaceuticals, Inc.

Over the last 12 months, insiders at Day One Biopharmaceuticals, Inc. have bought $undefined and sold $undefined worth of Day One Biopharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Day One Biopharmaceuticals, Inc. have bought $22.51M and sold $14.71M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 111,387 shares for transaction amount of $1.11M was made by AI Day1 LLC (10 percent owner) on 2023‑10‑20.

List of Insider Buy and Sell Transactions, Day One Biopharmaceuticals, Inc.

2026-02-17Sale
York Charles N II
COO and CFO
6,065
0.0058%
$11.60
$70,359
+79.80%
2026-02-17Sale
Bender Jeremy
CHIEF EXECUTIVE OFFICER
15,459
0.0147%
$11.60
$179,338
+79.80%
2026-02-17Sale
Dubow Adam
Gen Counsel & Secretary
6,395
0.0061%
$11.60
$74,188
+79.80%
2026-02-17Sale
Merendino Lauren
Chief Commercial Officer
5,814
0.0055%
$11.60
$67,448
+79.80%
2026-02-17Sale
VASCONCELLES MICHAEL
Head of Research and Dev.
2,728
0.0026%
$11.60
$31,647
+79.80%
2025-11-17Sale
York Charles N II
COO and CFO
4,062
0.004%
$8.91
$36,212
+28.28%
2025-11-17Sale
Bender Jeremy
CHIEF EXECUTIVE OFFICER
15,894
0.0156%
$8.91
$141,690
+28.28%
2025-11-17Sale
Dubow Adam
Gen Counsel & Secretary
4,319
0.0042%
$8.91
$38,503
+28.28%
2025-11-17Sale
Merendino Lauren
Chief Commercial Officer
3,726
0.0037%
$8.91
$33,216
+28.28%
2025-08-18Sale
York Charles N II
COO and CFO
4,106
0.004%
$6.77
$27,786
+36.34%
2025-08-18Sale
Bender Jeremy
CHIEF EXECUTIVE OFFICER
16,058
0.0156%
$6.77
$108,666
+36.34%
2025-08-18Sale
Dubow Adam
Gen Counsel & Secretary
4,365
0.0042%
$6.77
$29,538
+36.34%
2025-08-18Sale
Merendino Lauren
Chief Commercial Officer
3,766
0.0037%
$6.77
$25,485
+36.34%
2025-05-16Sale
York Charles N II
COO, CFO AND SECRETARY
4,282
0.0042%
$6.26
$26,796
+24.48%
2025-05-16Sale
Bender Jeremy
CHIEF EXECUTIVE OFFICER
13,964
0.0138%
$6.26
$87,385
+24.48%
2025-05-16Sale
Dubow Adam
GENERAL COUNSEL
4,552
0.0045%
$6.26
$28,486
+24.48%
2025-05-16Sale
Merendino Lauren
Chief Commercial Officer
3,927
0.0039%
$6.26
$24,575
+24.48%
2025-02-18Sale
York Charles N II
COO, CFO AND SECRETARY
4,370
0.0042%
$11.96
$52,278
-37.64%
2025-02-18Sale
Bender Jeremy
CHIEF EXECUTIVE OFFICER
12,048
0.0117%
$11.96
$144,130
-37.64%
2025-02-18Sale
Dubow Adam
GENERAL COUNSEL
4,646
0.0045%
$11.96
$55,580
-37.64%
Total: 162
*Gray background shows transactions not older than one year

DAWN Institutional Investors: Active Positions

Increased Positions128+59.53%17M+19.33%
Decreased Positions94-43.72%23M-25.33%
New Positions56New5MNew
Sold Out Positions41Sold Out10MSold Out
Total Postitions249+15.81%84M-6%

DAWN Ownership Change vs Market

No data is available at this moment.

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Fmr Llc$89,364.009.8%10.1M-1M-10.98%2025-09-30
Blackrock, Inc.$79,663.008.74%9M-828,976-8.43%2025-09-30
Atlas Venture Life Science Advisors, Llc$56,908.006.24%6.43M00%2025-09-30
Vanguard Group Inc$54,705.006%6.18M+4,834+0.08%2025-09-30
Deerfield Management Company, L.P.$41,643.004.57%4.71M+982,282+26.38%2025-09-30
Franklin Resources Inc$30,772.003.38%3.48M-620,599-15.14%2025-09-30
Rubric Capital Management Lp$29,887.003.28%3.38M+3MNew2025-09-30
State Street Corp$28,678.003.15%3.24M+550,758+20.48%2025-09-30
Vestal Point Capital, Lp$23,674.002.6%2.67M-325,000-10.83%2025-09-30
Pictet Asset Management Holding Sa$21,002.002.3%2.37M-1M-36.25%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.